Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274835 | 0.86 | DPP4 (0.51) | DPP4P2RX7 | |
| SCHEMBL9952433 | 0.84 | P2RX7 (0.42) | DPP4P2RX7 | |
| SCHEMBL9951661 | 0.82 | PARP1 (0.45) | DPP4P2RX7 | |
| SCHEMBL3230215 | 0.78 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL19547099 | 0.78 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL4268225 | 0.77 | DPP4 (0.52) | DPP4P2RX7 | |
| SCHEMBL4865954 | 0.77 | DPP4 (0.35) | DPP4P2RX7 | |
| SCHEMBL21315012 | 0.74 | GAA (0.33) | P2RX7 | |
| SCHEMBL4266981 | 0.73 | P2RX7 (0.45) | DPP4P2RX7 | |
| SCHEMBL3134418 | 0.73 | MAPK1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2475661-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029842-A1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | DPP4 4446/4885P2RX7 4552/4885GRM2 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.